

Neil R Poulter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5407431/publications.pdf>

Version: 2024-02-01

211
papers

32,517
citations

44444

50
h-index

4741

175
g-index

216
all docs

216
docs citations

216
times ranked

29956
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report. American Journal of Cardiovascular Drugs, 2022, 22, 251-261.	1.0	10
2	Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE. International Journal of Cardiology, 2022, 358, 103-109.	0.8	2
3	Global Impact of Different Blood Pressure Thresholds in 4690 Participants of the May Measurement Month Initiative. Hypertension, 2022, 79, 1497-1505.	1.3	4
4	Hypertension in stroke survivors and associations with national premature stroke mortality: data for 2.5 million participants from multinational screening campaigns. The Lancet Global Health, 2022, 10, e1141-e1149.	2.9	10
5	Additive association of knowledge and awareness on control of hypertension: a cross sectional survey in rural India. Journal of Hypertension, 2021, 39, 44-45.	0.3	1
6	May Measurement Month 2019: results of blood pressure screening from 47 countries. European Heart Journal Supplements, 2021, 23, B1-B5.	0.0	13
7	May Measurement Month 2019: an analysis of blood pressure screening results from Jamaica. European Heart Journal Supplements, 2021, 23, B82-B85.	0.0	0
8	May Measurement Month 2019: an analysis of blood pressure screening results from Ulaanbaatar, Mongolia. European Heart Journal Supplements, 2021, 23, B107-B109.	0.0	0
9	May Measurement Month 2019: an analysis of blood pressure screening results from Slovenia. European Heart Journal Supplements, 2021, 23, B131-B133.	0.0	3
10	May Measurement Month 2019: an analysis of blood pressure screening results from Kenya. European Heart Journal Supplements, 2021, 23, B86-B88.	0.0	1
11	May Measurement Month 2019: an analysis of blood pressure screening results from Venezuela, Latin America. European Heart Journal Supplements, 2021, 23, B151-B153.	0.0	0
12	May Measurement Month 2019: an analysis of blood pressure screening results from Ghana-Sub-Saharan Africa. European Heart Journal Supplements, 2021, 23, B62-B65.	0.0	2
13	May Measurement Month 2019: blood pressure screening results from Chile. European Heart Journal Supplements, 2021, 23, B40-B42.	0.0	0
14	May Measurement Month 2019: an analysis of blood pressure screening results from South Africa. European Heart Journal Supplements, 2021, 23, B134-B137.	0.0	2
15	May Measurement Month 2019: an analysis of blood pressure screening results from Cameroon. European Heart Journal Supplements, 2021, 23, B33-B36.	0.0	5
16	May Measurement Month 2019: an analysis of blood pressure screening results from Angola. European Heart Journal Supplements, 2021, 23, B9-B11.	0.0	1
17	Blood pressure screening results from May Measurement Month 2019 in Vietnam. European Heart Journal Supplements, 2021, 23, B154-B157.	0.0	3
18	May Measurement Month 2019: an analysis of blood pressure screening results from Ecuador. European Heart Journal Supplements, 2021, 23, B55-B58.	0.0	1

#	ARTICLE	IF	CITATIONS
19	May Measurement Month 2019: an analysis of blood pressure screening results from Nigeria. European Heart Journal Supplements, 2021, 23, B114-B116.	0.0	2
20	May Measurement Month 2019: an analysis of blood pressure screening results from Botswana. European Heart Journal Supplements, 2021, 23, B27-B29.	0.0	0
21	May Measurement Month 2019: an analysis of blood pressure screening results from Saudi Arabia. European Heart Journal Supplements, 2021, 23, B128-B130.	0.0	5
22	May Measurement Month 2019: an analysis of blood pressure screening results from Colombia. European Heart Journal Supplements, 2021, 23, B46-B48.	0.0	2
23	May Measurement Month 2019: an analysis of blood pressure screening results from Korea. European Heart Journal Supplements, 2021, 23, B89-B91.	0.0	3
24	May Measurement Month 2019: an analysis of blood pressure screening results from the Democratic Republic of the Congo. European Heart Journal Supplements, 2021, 23, B52-B54.	0.0	1
25	May Measurement Month 2019: an analysis of blood pressure screening results from Bangladesh. European Heart Journal Supplements, 2021, 23, B21-B23.	0.0	1
26	May Measurement Month 2019: an analysis of blood pressure screening results from Malaysia. European Heart Journal Supplements, 2021, 23, B98-B100.	0.0	0
27	May Measurement Month 2019: an analysis of blood pressure screening results from Mexico. European Heart Journal Supplements, 2021, 23, B104-B106.	0.0	2
28	May Measurement Month 2019: an analysis of blood pressure screening results from Taiwan. European Heart Journal Supplements, 2021, 23, B141-B143.	0.0	0
29	May Measurement Month 2019: an analysis of blood pressure screening results from Hungary. European Heart Journal Supplements, 2021, 23, B70-B72.	0.0	2
30	May Measurement Month 2019: an analysis of blood pressure screening results from Republic of the Congo. European Heart Journal Supplements, 2021, 23, B49-B51.	0.0	1
31	May Measurement Month 2019: an analysis of blood pressure screening results from Mauritius. European Heart Journal Supplements, 2021, 23, B101-B103.	0.0	0
32	Variation in hypertension clinical practice guidelines: a global comparison. BMC Medicine, 2021, 19, 117.	2.3	19
33	May Measurement Month 2019: an analysis of blood pressure screening results from Tunisia. European Heart Journal Supplements, 2021, 23, B144-B146.	0.0	1
34	May Measurement Month 2019: an analysis of blood pressure screening results from Lebanon. European Heart Journal Supplements, 2021, 23, B92-B94.	0.0	3
35	May Measurement Month 2019: an analysis of blood pressure screening results from Spain. European Heart Journal Supplements, 2021, 23, B138-B140.	0.0	3
36	May Measurement Month 2019: an analysis of blood pressure screening results from Zambia. European Heart Journal Supplements, 2021, 23, B158-B160.	0.0	1

#	ARTICLE	IF	CITATIONS
37	May Measurement Month 2019: an analysis of blood pressure screening results from Armenia. European Heart Journal Supplements, 2021, 23, B15-B17.	0.0	0
38	May Measurement Month 2019: an analysis of blood pressure screening results from Malawi. European Heart Journal Supplements, 2021, 23, B95-B97.	0.0	1
39	May Measurement Month 2019: an analysis of blood pressure screening results from Cape Verde. European Heart Journal Supplements, 2021, 23, B37-B39.	0.0	1
40	May Measurement Month 2019: an analysis of blood pressure screening results in the Philippines. European Heart Journal Supplements, 2021, 23, B120-B123.	0.0	1
41	May Measurement Month 2019: an analysis of blood pressure screening results from China. European Heart Journal Supplements, 2021, 23, B43-B45.	0.0	3
42	May Measurement Month 2019: an analysis of blood pressure screening results from Albania. European Heart Journal Supplements, 2021, 23, B6-B8.	0.0	0
43	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2021, 23, B77-B81.	0.0	4
44	May Measurement Month 2019: an analysis of blood pressure screening results from Benin—Sub-Saharan Africa. European Heart Journal Supplements, 2021, 23, B24-B26.	0.0	0
45	May Measurement Month 2019: an analysis of blood pressure screening results from the United Kingdom and Republic of Ireland. European Heart Journal Supplements, 2021, 23, B147-B150.	0.0	2
46	May Measurement Month 2019: an analysis of blood pressure screening results from Australia. European Heart Journal Supplements, 2021, 23, B18-B20.	0.0	3
47	May Measurement Month 2019: blood pressure screening results in Georgia, Europe. European Heart Journal Supplements, 2021, 23, B59-B61.	0.0	0
48	May Measurement Month 2019: an analysis of blood pressure screening results from Brazil. European Heart Journal Supplements, 2021, 23, B30-B32.	0.0	1
49	May Measurement Month 2019: an analysis of blood pressure screening results from Poland. European Heart Journal Supplements, 2021, 23, B124-B127.	0.0	2
50	May Measurement Month 2019: an analysis of blood pressure screening results from Argentina. European Heart Journal Supplements, 2021, 23, B12-B14.	0.0	1
51	High prevalence of non-dipping patterns among Black Africans with uncontrolled hypertension: a secondary analysis of the CREOLE trial. BMC Cardiovascular Disorders, 2021, 21, 254.	0.7	9
52	May Measurement Month 2019: an analysis of blood pressure screening results from India. European Heart Journal Supplements, 2021, 23, B73-B76.	0.0	1
53	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. Diabetologia, 2021, 64, 2012-2025.	2.9	24
54	The factors influencing clinician use of hypertension guidelines in different resource settings: a qualitative study investigating clinicians' perspectives and experiences. BMC Health Services Research, 2021, 21, 767.	0.9	2

#	ARTICLE	IF	CITATIONS
55	World Heart Federation Roadmap for Hypertension – A 2021 Update. <i>Global Heart</i> , 2021, 16, 63.	0.9	56
56	Prevalence of high blood pressure and cardiovascular risk factors from a community screening programme in the Middle-East; a 3-year analysis of data from the May Measurement Month programme (2017–2019) in Oman. <i>Journal of Human Hypertension</i> , 2021, , .	1.0	1
57	The power of genetic diversity in genome-wide association studies of lipids. <i>Nature</i> , 2021, 600, 675-679.	13.7	353
58	Medication adherence in hypertension. <i>Journal of Hypertension</i> , 2020, 38, 579-587.	0.3	55
59	May Measurement Month 2018: an analysis of blood pressure screening results from Nepal. <i>European Heart Journal Supplements</i> , 2020, 22, H92-H95.	0.0	5
60	May Measurement Month 2018: an analysis of blood pressure screening in Libya. <i>European Heart Journal Supplements</i> , 2020, 22, H77-H79.	0.0	0
61	May Measurement Month 2018: results of blood pressure screening from 41 countries. <i>European Heart Journal Supplements</i> , 2020, 22, H1-H4.	0.0	5
62	May Measurement Month 2018: an analysis of blood pressure screening results from Albania. <i>European Heart Journal Supplements</i> , 2020, 22, H5-H7.	0.0	2
63	May Measurement Month 2018: an analysis of blood pressure screening results from Angola. <i>European Heart Journal Supplements</i> , 2020, 22, H8-H10.	0.0	2
64	May Measurement Month 2018: an analysis of blood pressure screening results from Argentinean cohort. <i>European Heart Journal Supplements</i> , 2020, 22, H11-H13.	0.0	2
65	An analysis of blood pressure screening of 21 112 participants in Armenia: May Measurement Month 2018. <i>European Heart Journal Supplements</i> , 2020, 22, H14-H16.	0.0	1
66	May Measurement Month 2018: an analysis of blood pressure screening results from Australia. <i>European Heart Journal Supplements</i> , 2020, 22, H17-H19.	0.0	4
67	May Measurement Month 2018: an analysis of blood pressure screening results from Botswana. <i>European Heart Journal Supplements</i> , 2020, 22, H23-H25.	0.0	2
68	May Measurement Month 2018: an analysis of blood pressure screening results from Chile. <i>European Heart Journal Supplements</i> , 2020, 22, H37-H39.	0.0	1
69	May Measurement Month 2018: an analysis of blood pressure screening results from China. <i>European Heart Journal Supplements</i> , 2020, 22, H40-H42.	0.0	6
70	May Measurement Month 2018: an analysis of blood pressure screening results from Republic of the Congo. <i>European Heart Journal Supplements</i> , 2020, 22, H47-H49.	0.0	4
71	Analysis of blood pressure and selected cardiovascular risk factors in the Democratic Republic of the Congo: the May Measurement Month 2018 results. <i>European Heart Journal Supplements</i> , 2020, 22, H50-H52.	0.0	3
72	May Measurement Month 2018: an analysis of blood pressure screening results in Georgia. <i>European Heart Journal Supplements</i> , 2020, 22, H56-H58.	0.0	1

#	ARTICLE	IF	CITATIONS
73	May Measurement Month 2018: an analysis of blood pressure screening results from Ghana. European Heart Journal Supplements, 2020, 22, H59-H61.	0.0	6
74	May Measurement Month 2018: an analysis of blood pressure screening campaign results in India. European Heart Journal Supplements, 2020, 22, H62-H65.	0.0	2
75	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2020, 22, H70-H73.	0.0	4
76	May Measurement Month 2018: an analysis of blood pressure screening from Kenya. European Heart Journal Supplements, 2020, 22, H74-H76.	0.0	1
77	May Measurement Month 2018: an analysis of blood pressure screening results from Malawi. European Heart Journal Supplements, 2020, 22, H80-H82.	0.0	2
78	May Measurement Month 2018: an analysis of blood pressure screening results from Malaysia. European Heart Journal Supplements, 2020, 22, H83-H85.	0.0	4
79	May Measurement Month 2018: an analysis of blood pressure screening results from Oman. European Heart Journal Supplements, 2020, 22, H100-H103.	0.0	2
80	May Measurement Month 2018: an analysis of blood pressure screening in the Philippines. European Heart Journal Supplements, 2020, 22, H104-H107.	0.0	3
81	May Measurement Month 2018: an analysis of blood pressure screening campaign results from Poland. European Heart Journal Supplements, 2020, 22, H108-H111.	0.0	4
82	May Measurement Month 2018: an analysis of blood pressure screening results from Slovenia. European Heart Journal Supplements, 2020, 22, H112-H114.	0.0	1
83	May Measurement Month 2018: an analysis of blood pressure screening results from Sudan. European Heart Journal Supplements, 2020, 22, H122-H124.	0.0	3
84	May Measurement Month 2018: an analysis of blood pressure screening results from United Arab Emirates. European Heart Journal Supplements, 2020, 22, H128-H131.	0.0	3
85	Results of May Measurement Month 2018 campaign in Venezuela. European Heart Journal Supplements, 2020, 22, H135-H138.	0.0	1
86	May Measurement Month 2018: an analysis of blood pressure screening results from Vietnam. European Heart Journal Supplements, 2020, 22, H139-H141.	0.0	4
87	May Measurement Month 2018: an analysis of blood pressure screening results from Brazil. European Heart Journal Supplements, 2020, 22, H26-H29.	0.0	1
88	May Measurement Month 2018: an analysis of blood pressure screening results from Spain. European Heart Journal Supplements, 2020, 22, H119-H121.	0.0	5
89	May Measurement Month 2018: an analysis of blood pressure screening results from Nigeria. European Heart Journal Supplements, 2020, 22, H96-H99.	0.0	2
90	May Measurement Month 2018: an analyses of blood pressure screening results from Cabo Verde. European Heart Journal Supplements, 2020, 22, H30-H32.	0.0	2

#	ARTICLE	IF	CITATIONS
91	May Measurement Month 2018: an analysis of blood pressure screening results from Colombia. European Heart Journal Supplements, 2020, 22, H43-H46.	0.0	2
92	May Measurement Month 2018: an analysis of blood pressure screening results from Indonesia. European Heart Journal Supplements, 2020, 22, H66-H69.	0.0	4
93	May Measurement Month 2018: an analysis of blood pressure screening results from Mexico. European Heart Journal Supplements, 2020, 22, H89-H91.	0.0	2
94	May Measurement Month 2018: an analysis of blood pressure screening results in South Africa. European Heart Journal Supplements, 2020, 22, H115-H118.	0.0	1
95	May Measurement Month 2018: an analysis of blood pressure screening results from the UK and the Republic of Ireland. European Heart Journal Supplements, 2020, 22, H132-H134.	0.0	1
96	May Measurement Month 2018: an analysis of blood pressure screening results from Bangladesh. European Heart Journal Supplements, 2020, 22, H20-H22.	0.0	2
97	May Measurement Month 2018: an analysis of blood pressure screening results from Taiwan. European Heart Journal Supplements, 2020, 22, H125-H127.	0.0	3
98	May Measurement Month 2018: blood pressure screening results in Cameroon. European Heart Journal Supplements, 2020, 22, H33-H36.	0.0	2
99	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). Diabetes and Vascular Disease Research, 2020, 17, 147916412097093.	0.9	6
100	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	4.3	92
101	May Measurement Month 2019. Hypertension, 2020, 76, 333-341.	1.3	157
102	2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 2020, 75, 1334-1357.	1.3	1,895
103	May measurement month 2017: Latin America. Journal of Hypertension, 2020, 38, 1183-1188.	0.3	13
104	2020 International Society of Hypertension global hypertension practice guidelines. Journal of Hypertension, 2020, 38, 982-1004.	0.3	452
105	Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. Diabetologia, 2020, 63, 1637-1647.	2.9	16
106	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. Journal of the American College of Cardiology, 2020, 75, 1128-1141.	1.2	53
107	Potassium Intake in India: Opportunity for Mitigating Risks of High-Sodium Diets. American Journal of Preventive Medicine, 2020, 58, 302-312.	1.6	6
108	Chronotherapy in hypertension: the devil is in the details. European Heart Journal, 2020, 41, 1606-1607.	1.0	18

#	ARTICLE	IF	CITATIONS
109	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 465-473.	2.2	32
110	A collaborative model for capacity building of primary care physicians in the management of Hypertension in India. <i>Journal of Human Hypertension</i> , 2019, 33, 562-565.	1.0	5
111	Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: A propensity score-matched cohort study in the UK Clinical Practice Research Datalink. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1572-1582.	0.9	14
112	Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. <i>American Journal of Epidemiology</i> , 2019, 188, 1033-1054.	1.6	85
113	May Measurement Month 2017: an analysis of blood pressure screening in the Philippines-South-East Asia and Australasia. <i>European Heart Journal Supplements</i> , 2019, 21, D92-D96.	0.0	5
114	May Measurement Month 2017: an analysis of blood pressure screening results in Georgia-Europe. <i>European Heart Journal Supplements</i> , 2019, 21, D53-D55.	0.0	2
115	Results of the May Measurement Month 2017: blood pressure campaign in Venezuela-Americas. <i>European Heart Journal Supplements</i> , 2019, 21, D124-D126.	0.0	3
116	Do we know more about hypertension in Poland after the May Measurement Month 2017? Europe. <i>European Heart Journal Supplements</i> , 2019, 21, D97-D100.	0.0	6
117	May Measurement Month 2017: an analysis of blood pressure screening results in Austria-Europe. <i>European Heart Journal Supplements</i> , 2019, 21, D17-D20.	0.0	3
118	May Measurement Month 2017: an analysis of blood pressure screening results in China-East Asia. <i>European Heart Journal Supplements</i> , 2019, 21, D37-D39.	0.0	10
119	May Measurement Month 2017: Blood pressure screening results from Zambia-Sub-Saharan Africa. <i>European Heart Journal Supplements</i> , 2019, 21, D130-D132.	0.0	6
120	May Measurement Month 2017: analysis of the blood pressure screening results in Argentina-Americas. <i>European Heart Journal Supplements</i> , 2019, 21, D8-D10.	0.0	5
121	May Measurement Month 2017: an analysis of blood pressure screening results in Armenia-Europe. <i>European Heart Journal Supplements</i> , 2019, 21, D11-D13.	0.0	3
122	May Measurement Month 2017: an analysis of blood pressure screening in Hungary-Europe. <i>European Heart Journal Supplements</i> , 2019, 21, D56-D58.	0.0	2
123	May Measurement Month 2017: Results of 39 national blood pressure screening programmes. <i>European Heart Journal Supplements</i> , 2019, 21, D1-D4.	0.0	13
124	May Measurement Month 2017: the results of blood pressure screening of 14,845 individuals in Kenya-Sub-Saharan Africa. <i>European Heart Journal Supplements</i> , 2019, 21, D71-D73.	0.0	7
125	May Measurement Month 2017: an analysis of blood pressure screening results in Nepal-South Asia. <i>European Heart Journal Supplements</i> , 2019, 21, D83-D85.	0.0	7
126	May Measurement Month 2017: screening for hypertension in Nigeria-Sub-Saharan Africa. <i>European Heart Journal Supplements</i> , 2019, 21, D86-D88.	0.0	4

#	ARTICLE	IF	CITATIONS
127	Rates of untreated, treated, and controlled hypertension and relationships between blood pressure with other cardiovascular risk factors in Brazzaville (Republic of the Congo): May Measurement Month 2017â€™Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D44-D46.	0.0	5
128	May Measurement Month 2017: an analysis of the blood pressure screening campaign results in Indonesiaâ€™South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D63-D65.	0.0	4
129	May Measurement Month 2017: results of a blood pressure screening campaign in Malawiâ€™Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D74-D76.	0.0	5
130	May Measurement Month 2017: an analysis of blood pressure screening results from the United Kingdom and the Republic of Irelandâ€™Europe. European Heart Journal Supplements, 2019, 21, D121-D123.	0.0	7
131	May Measurement Month 2017: an analysis of blood pressure screening results from the United Arab Emiratesâ€™Northern Africa and Middle East. European Heart Journal Supplements, 2019, 21, D118-D120.	0.0	7
132	May Measurement Month 2017 in Chileâ€™Americas. European Heart Journal Supplements, 2019, 21, D34-D36.	0.0	4
133	May Measurement Month 2017: an analysis of blood pressure screening in Angolaâ€™Subâ€™Saharan Africa. European Heart Journal Supplements, 2019, 21, D5-D7.	0.0	4
134	May Measurement Month 2017: an analysis of blood pressure screening results from Australiaâ€™South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D14-D16.	0.0	6
135	May Measurement Month 2017 blood pressure screening: findings from Malaysiaâ€™South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D77-D79.	0.0	20
136	May Measurement Month 2017 in Russia: hypertension treatment and controlâ€™Europe. European Heart Journal Supplements, 2019, 21, D101-D103.	0.0	6
137	May Measurement Month 2017: an analysis of blood pressure screening in Spainâ€™Europe. European Heart Journal Supplements, 2019, 21, D107-D110.	0.0	3
138	May Measurement Month (MMM) 2017: an analysis of blood pressure screening results in Bangladeshâ€™South Asia. European Heart Journal Supplements, 2019, 21, D21-D24.	0.0	3
139	MMM17-Cameroon, analysis and opportunitiesâ€™Sub-Saharan Africa. European Heart Journal Supplements, 2019, 21, D31-D33.	0.0	10
140	May Measurement Month 2017: an analysis of blood pressure screening results in Colombiaâ€™Americas. European Heart Journal Supplements, 2019, 21, D40-D43.	0.0	4
141	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	1.0	193
142	May Measurement Month 2017: Brazilian resultsâ€™Americas. European Heart Journal Supplements, 2019, 21, D25-D27.	0.0	6
143	Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. New England Journal of Medicine, 2019, 380, 2429-2439.	13.9	85
144	Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. American Journal of Cardiovascular Drugs, 2019, 19, 313-323.	1.0	9

#	ARTICLE	IF	CITATIONS
145	Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. <i>Nature Genetics</i> , 2019, 51, 636-648.	9.4	112
146	Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension. <i>Journal of Hypertension</i> , 2019, 37, 2216-2224.	0.3	7
147	May Measurement Month 2017: an analysis of blood pressure screening results in South Africa-Sub-Saharan Africa. <i>European Heart Journal Supplements</i> , 2019, 21, D104-D106.	0.0	3
148	Rationale and design of the comparison of 3 combination therapies in lowering blood pressure in black Africans (CREOLE study): 2 × 3 factorial randomized single-blind multicenter trial. <i>American Heart Journal</i> , 2018, 202, 5-12.	1.2	9
149	Hypertension. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18014.	18.1	636
150	Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition. <i>Lancet, The</i> , 2018, 391, 1224-1236.	6.3	101
151	Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure. <i>Hypertension</i> , 2018, 72, 870-873.	1.3	54
152	Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. <i>Nature Genetics</i> , 2018, 50, 1412-1425.	9.4	924
153	May Measurement Month 2017: an analysis of blood pressure screening results worldwide. <i>The Lancet Global Health</i> , 2018, 6, e736-e743.	2.9	245
154	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. <i>Circulation</i> , 2018, 137, 2179-2183.	1.6	80
155	Are the American Heart Association/American College of Cardiology High Blood Pressure Guidelines Fit for Global Purpose?: Thoughts From the International Society of Hypertension. <i>Hypertension</i> , 2018, 72, 260-262.	1.3	20
156	Blood pressure measurement in special populations and circumstances. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1122-1127.	1.0	20
157	Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. <i>Lancet, The</i> , 2018, 392, 1127-1137.	6.3	87
158	Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries. <i>PLoS ONE</i> , 2018, 13, e0198166.	1.1	94
159	Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. <i>Nature Genetics</i> , 2017, 49, 403-415.	9.4	492
160	Discovery of novel heart rate-associated loci using the Exome Chip. <i>Human Molecular Genetics</i> , 2017, 26, 2346-2363.	1.4	29
161	May Measurement Month: a global blood pressure screening campaign. <i>Lancet, The</i> , 2017, 389, 1678-1680.	6.3	25
162	May Measurement Month. <i>Journal of Hypertension</i> , 2017, 35, 1126-1128.	0.3	21

#	ARTICLE	IF	CITATIONS
163	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 723-732.	13.9	480
164	Prognostic Impact of In-Hospital and Postdischarge Heart Failure in Patients With Acute Myocardial Infarction: A Nationwide Analysis Using Data From the Cardiovascular Disease in Norway (CVDNOR) Project. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	25
165	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 839-848.	13.9	903
166	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	13.9	1,455
167	Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment – a clinical appraisal. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1451-1457.	1.2	3
168	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. <i>Clinical Research in Cardiology</i> , 2017, 106, 58-68.	1.5	23
169	An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK). <i>European Heart Journal</i> , 2016, 37, 3213-3221.	1.0	80
170	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 213-221.	0.9	12
171	Is It Time to Reappraise Blood Pressure Thresholds and Targets?. <i>Hypertension</i> , 2016, 68, 266-268.	1.3	16
172	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2016, 134, 1637-1650.	1.6	205
173	Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. <i>Value in Health</i> , 2016, 19, 36-41.	0.1	83
174	The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax) Tj ETQq0 00sgBT /Overlock 10	0.8	10
175	An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK). <i>Health Technology Assessment</i> , 2016, 20, 1-180.	1.3	19
176	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. <i>Lancet, The</i> , 2015, 385, 2264-2271.	6.3	564
177	Hypertension. <i>Lancet, The</i> , 2015, 386, 801-812.	6.3	539
178	Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. <i>Global Heart</i> , 2015, 10, 111.	0.9	104
179	Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. <i>Diabetologia</i> , 2014, 57, 2465-2474.	2.9	346
180	Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial. <i>Diabetes Care</i> , 2014, 37, 2359-2365.	4.3	284

#	ARTICLE	IF	CITATIONS
181	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2014, 371, 1392-1406.	13.9	520
182	Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial. <i>Diabetes Care</i> , 2014, 37, 2202-2210.	4.3	32
183	Hypertension management in England: a serial cross-sectional study from 1994 to 2011. <i>Lancet, The</i> , 2014, 383, 1912-1919.	6.3	226
184	Commentary: Shaper and Jones, 'Serum-cholesterol, diet and coronary heart-disease in Africans and Asians in Uganda': 50-year-old findings only need interpretational fine tuning to come up to speed!. <i>International Journal of Epidemiology</i> , 2012, 41, 1228-1230.	0.9	2
185	Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial—Blood Pressure Lowering Arm (ASCOT-BPLA). <i>Journal of Hypertension</i> , 2011, 29, 583-591.	0.3	32
186	A new dimension in hypertension management with the amlodipine/perindopril combination. <i>Journal of Hypertension</i> , 2011, 29, S15-S21.	0.3	3
187	Effects of β^2 blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. <i>Lancet Neurology, The</i> , 2010, 9, 469-480.	4.9	634
188	Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. <i>Lancet, The</i> , 2010, 375, 895-905.	6.3	1,525
189	Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. <i>Hypertension</i> , 2010, 55, 399-407.	1.3	579
190	Continued Improvement in Hypertension Management in England. <i>Hypertension</i> , 2009, 53, 480-486.	1.3	190
191	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2068-2074.	4.3	230
192	Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1813-1821.	3.0	787
193	Coronary heart disease benefits from blood pressure and lipid-lowering. <i>International Journal of Cardiology</i> , 2009, 135, 218-222.	0.8	9
194	Baseline Heart Rate, Antihypertensive Treatment, and Prevention of Cardiovascular Outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). <i>Journal of the American College of Cardiology</i> , 2009, 54, 1154-1161.	1.2	63
195	Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. <i>Journal of Hypertension</i> , 2009, 27, 947-954.	0.3	30
196	Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. <i>Journal of Hypertension</i> , 2009, 27, S3-S8.	0.3	25
197	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 358, 2560-2572.	13.9	6,447
198	The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. <i>Journal of Hypertension</i> , 2008, 26, 2103-2111.	0.3	98

#	ARTICLE	IF	CITATIONS
199	Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. <i>Hypertension</i> , 2007, 49, 839-845.	1.3	583
200	Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. <i>European Heart Journal</i> , 2006, 27, 2982-2988.	1.0	146
201	Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2005, 366, 895-906.	6.3	2,662
202	Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). <i>Lancet, The</i> , 2005, 366, 907-913.	6.3	314
203	Measures of Global Risk: Old Versus New Methods. <i>Clinical and Experimental Hypertension</i> , 2004, 26, 653-662.	0.5	1
204	Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). <i>Drugs</i> , 2004, 64, 43-60.	4.9	189
205	Hypertension Treatment and Control in Five European Countries, Canada, and the United States. <i>Hypertension</i> , 2004, 43, 10-17.	1.3	944
206	Past, present, and future clinical trials of cardiovascular risk reduction—the hyperlipidemia perspective. <i>International Congress Series</i> , 2004, 1262, 265-268.	0.2	1
207	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2003, 361, 1149-1158.	6.3	3,420
208	Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. <i>Journal of Hypertension</i> , 2001, 19, 1139-1147.	0.3	234
209	Association Between Smoking and Blood Pressure. <i>Hypertension</i> , 2001, 37, 187-193.	1.3	348
210	Ethnic Differences in the Hypertensive Heart and 24-Hour Blood Pressure Profile. <i>Hypertension</i> , 1998, 31, 1190-1194.	1.3	57
211	Psycho-Emotional Stress and Salt Intake May Interact to Raise Blood Pressure. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1994, 1, 45-51.	3.1	7